Preventing mother-to-child transmission of HIV in resource-limited settings

Future Virology

Volumn 4, Issue 2, 2009, Pages 165-175

  Maheswaran, Hendramoorthy ^a   Bland, Ruth M ^a,b  

^a AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

ARV; Breastfeeding; HIV; Mother to child transmission; PMTCT; Pregnancy

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; ZIDOVUDINE;

ANTIVIRAL THERAPY; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; DRUG DOSE REGIMEN; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MOTHER CHILD RELATION; PATIENT COUNSELING; PERINATAL INFECTION; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 70349222907     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.4.2.165     Document Type: Review

References (115)

1. Newell ML: Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS 12(8), 831-837 (1998).
2. Rouzioux C, Costagliola D, Burgard M et al.: Timing of mother-to-child HIV-1 transmission depends on maternal status. The HIV Infection in Newborns French Collaborative Study Group. AIDS 7(Suppl. 2), S49-S52 (1993).
3. Kuhn L, Thea DM, Aldrovandi GM: Bystander effects: children who escape infection but not harm. J. Acquir. Immune Defic. Syndr. 46(5), 517-518 (2007).
4. Marinda E, Humphrey JH, Iliff PJ et al.: Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr. Infect. Dis. J. 26(6), 519-526 (2007).
5. Thea DM, St Louis ME, Atido U et al.: A prospective study of diarrhea and HIV-1 infection among 429 Zairian infants. N. Engl. J. Med. 329(23), 1696-1702 (1993).
6. Crampin AC, Floyd S, Glynn JR et al.: The long-term impact of HIV and orphanhood on the mortality and physical well-being of children in rural Malawi. AIDS 17(3), 389-397 (2003).
7. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F: Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364(9441), 1236-1243 (2004).
8. Cooper ER, Charurat M, Mofenson L et al.: Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinacal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. 29(5), 484-494 (2002).
9. Dorenbaum A, Cunningham CK, Gelber RD et al.: Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 288(2), 189-198 (2002).
10. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 40(3), 458-465 (2005).
11. Dabis F, Bequet L, Ekouevi DK et al.: Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 19(3), 309-318 (2005).
12. Lallemant M, Jourdain G, Le Coeur S et al.: Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med. 351(3), 217-228 (2004).
13. Leroy V, Sakarovitch C, Cortina-Borja M et al.: Is there a difference in the efficacy of periparturn antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa? AIDS 19(16), 1865-1875 (2005).
14. UNAIDS. Report on the global HIV/AIDS epidemic. UNAIDS, Geneva, Switzerland, July 2002.
15. Luo C, Akwara P, Ngongo N et al.: Global progress in PMTCT and paediatric HIV care and treatment in low- and middle-income countries in 2004-2005. Reprod. Health Matters 15(30), 179-189 (2007).
16. Ginsburg AS, Hoblitzelle CW, Sripipatana TL, Wilfert CM: Provision of care following prevention of mother-to-child HIV transmission services in resource-limited settings. AIDS 21(18), 2529-2532 (2007).
17. Manzi M, Zachariah R, Teck R et al.: High acceptability of voluntary counseling and HIV-testing but unacceptable loss to follow-up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. Trop. Med. Int. Health 10(12), 1242-1250 (2005).
18. Perez F, Orne-Gliemann J, Mukotekwa T et al.: Prevention of mother to child transmission of HIV: evaluation of a pilot programme in a district hospital in rural Zimbabwe. BMJ 329(7475), 1147-1150 (2004).
19. Temmerman M, Quaghebeur A, Mwanyumba F, Mandaliya K: Mother-to-child HIV transmission in resource poor settings: how to improve coverage? AIDS 17(8), 1239-1242 (2003).
20. Bajunirwe F, Muzoora M: Barriers to the implementation of programs for the prevention of mother-to-child transmission of HIV: a cross-sectional survey in rural and urban Uganda. AIDS Res. Ther. 2, 10 (2005).
21. Behets FM, Matendo R, Vaz LM et al.: Preventing vertical transmission of HIV in Kinshasa, Democratic Republic of the Congo: a baseline survey of 18 antenatal clinics. Bull. World Health Organ. 84(12), 969-975 (2006).
22. Galvan FH, Brooks RA, Leibowitz AA: Rapid HIV testing: issues in implementation. AIDS Patient Care STDS 18(1), 15-18 (2004).
23. Hutchinson PL, Mahlalela X: Utilization of voluntary counseling and testing services in the Eastern Cape, South-Africa. AIDS Care 18(5), 446-455 (2006).
24. Jackson DJ, Chopra M, Doherty TM et al.: Operational effectiveness and 36 week HIV-free survival in the South African programme to prevent mother-to-child transmission of HIV-1. AIDS 21(4), 509-516 (2007).
25. Kalichman SC, Simbayi LC: HIV testing attitudes, AIDS stigma, and voluntary HIV counseling and testing in a black township in Cape Town, South Africa. Sex. Transm. Infect. 79(6), 442-447 (2003).
26. Matovu JK, Gray RH, Makumbi F et al.: Voluntary HIV counseling and testing acceptance, sexual risk behavior and HIV incidence in Rakai, Uganda. AIDS 19(5), 503-511 (2005).
27. Perez-Then E, Pena R, Tavarez-Rojas M et al.: Preventing mother-to-child HIV transmission in a developing country: the Dominican Republic experience. J. Acquir. Immune Defic. Syndr. 34(5), 506-511 (2003).
28. Pignatelli S, Simpore J, Pietra V et al.: Factors predicting uptake of voluntary counseling and testing in a real-life setting in a mother-and-child center in Ouagadougou, Burkina Faso. Trop. Med. Int. Health 11(3), 350-357 (2006).
29. Thielman NM, Chu HY, Ostermann J et al.: Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. Am. J. Public Health 96(1), 114-119 (2006).
30. Ekouevi DK, Leroy V, Viho A et al.: Acceptability and uptake of a package to prevent mother-to-child transmission using rapid HIV testing in Abidjan, Cote d'Ivoire. AIDS 18(4), 697-700 (2004).
31. Mkwanazi NB, Patel D, Newell ML et al.: Rapid testing may not improve uptake of HIV resting and same day results in a rural South African community: a cohort study of 12,000 women. PLoS ONE 3(10), e3501 (2008).
32. Chandisarewa W, Stranix-Chibanda L, Chirapa E et al.: Routine offer of antenatal HIV testing ('opt-out' approach) to prevent mother-to-child transmission of HIV in urban Zimbabwe. Bull. World Health Organ. 85(11), 843-850 (2007).
33. WHO and UNICEF. Guidance on global scale-up of the prevention of mother-to-child transmission of HIV: towards universal access for women, infants and young chidlren and eliminating HIV and AIDS among children. WHO, Geneva, Switzerland (2007).
34. Gray RH, Li X, Kigozi G et al.: Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 366(9492), 1182-1188 (2005).
35. Leroy V: Maternal plasma viral load, zidovudine and mother-to-child transmission of HIV in Africa: DITRAME ANRS 049a trial. AIDS 15(4), 517-522 (2001).
36. Shapiro RL, Holland DT, Capparelli E et al.: Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J. Infect. Dis. 192(5), 720-727 (2005).
37. Connor EM, Sperling RS, Gelber R et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 331(18), 1173-1180 (1994).
38. No authors listed. 15-month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children. DITRAME ANRS 049 Study Group. Lancet 354(9195), 2050-2051 (1999).
39. Dabis F, Msellati P, Meda N et al.: 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant. Lancet 353(9155), 786-792 (1999).
40. Meda N, Leroy V, Vihoz I et al.: Field acceptability and effectiveness of the routine utilization of zidovudine to reduce mother-to-child transmission of HIV-1 in West Africa. AIDS 16(17), 2323-2328 (2002).
41. Wiktor SZ, Ekpini E, Karon JM et al.: Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 353(9155), 781-785 (1999).
42. Guay LA, Musoke P, Fleming T et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354(9181), 795-802 (1999).
43. Jackson JB, Musoke P, Fleming T et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362(9387), 859-868 (2003).
44. PETRA: Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (PETRA study): a randomised, double-blind, placebo-controlled trial. Lancet 359(9313), 1178-1186 (2002).
45. Thistle P, Spitzer RF, Glazier RH et al.: A randomized, double-blind, placebo- controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe. Clin. Infect. Dis. 44(1), 111-119 (2007).
46. Artive E, Newell ML, Ekouevi DK et al.: Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int. J. Epidemiol. 36(5), 1009-1021 (2007).
47. Eshleman SH, Guay LA, Mwatha A et al.: Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose NVP prophylaxis: HIVNET 012. AIDS Res. Hum. Retroviruses 20(6), 595-599 (2004).
48. Eshleman SH, Hoover DR, Chen S et al.: Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J. Infect. Dis. 192(1), 30-36 (2005).
49. Chi BH, Sinkala M, Stringer EM et al.: Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 21(8), 957-964 (2007).
50. Iackman S, Shapiro RL, Smeaton LM et al.: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med. 356(2), 135-147 (2007).
51. Coffie PA, Ekouevi DK, Chaix ML et al.: Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin. Infect. Dis. 46(4), 611-621 (2008).
52. Stover J, Walker N, Grassly NC, Marston M: Projecting the demographic impact of AIDS and the number of people in need of treatment: updates to the Spectrum Projection Package. Sex. Transm. Infect. 82(Suppl. 3.), iii45-iii50 (2006).
53. Abrams EJ, Wiener J, Carter R et al.: Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS 17(6), 867-877 (2003).
54. Ioannidis JP, Abrams EJ, Ammann A et al.: Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J. Infect. Dis. 183(4), 539-545 (2001).
55. Ioannidis JP, Tatsioni A, Abrams EJ et al.: Maternal viral load and rate of disease progression among vertically HIV-1-infected children: an-international meta-analysis. AIDS 18(1), 99-108 (2004).
56. Ekouevi DK, Coffie PA, Becquet R et al.: Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS 22(14), 1815-1820 (2008).
57. Bae WH, Wester C, Smeaton LM et al.: Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. AIDS 22(13), 1633-1640 (2008).
58. European Collaborative Study. Increased risk of adverse pregancy outcomes in HAART-treated HIV-infected women in Europe. AIDS 17, 2913-2920 (2004).
59. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ: Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J. Infect. Dis. 193(9), 1195-1201 (2006).
60. Thorne C, Patel D, Newell ML: Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 18(17), 2337-2339 (2004).
61. Baylor MS, Johann-Liang R: Hepatotoxicity associated with nevirapine use. J. Acquir. Immune Defic. Syndr. 35(5), 538-539 (2004).
62. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL: A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J. Acquir. Immune Defic. Syndr. 34(Suppl. 1), S21-S33 (2003).
63. Timmermans S, Tempelman C, Godfried MH et al.: Nelfinavir and nevirapine side effects during pregnancy. AIDS 19(8), 795-799 (2005).
64. Suy A, Martinez E, Coll O et al.: Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 20(1), 59-66 (2006).
65. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers. AIDS 18(13), 2009-2017 (2004).
66. Bunders MJ, Bekker V, Scherpbier HJ, Boer K, Godfried M, Kuijpers TW: Haematological parameters ofHIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr. 94(11), 1571-1577 (2005).
67. Le Chenadec J, Mayaux MJ, Guiheuneuc-Jouyaux C, Blanche S: Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 17(14), 2053-2061 (2003).
68. Black RE, Morris SS, Bryce J: Where and why are 10 Million children dying every year? Lancet 361(9376), 2226-2234 (2003).
69. WHO. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: a pooled analysis. WHO Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality. Lancet 355 (9202), 451-455 (2000).
70. Coutsoudis A: Promotion of exclusive breastfeeding in the face of the HIV pandemic. Lancet 356(9242), 1620-1621 (2000).
71. Coutsoudis A, Goga AE, Rollins N, Coovadia HM: Free formula milk for infants of HIV-infected women: blessing or curse? Health Policy Plan. 17(2), 154-160 (2002).
72. Nicoll A, Newell ML, Peckham C, Luo C, Savage F: Infant feeding and HIV-1 infection. AIDS 14(Suppl. 3), S57-S74 (2000).
73. Schwartlander B, Stover J, Walker N et al.: AIDS. Resource needs for HIV/AIDS. Science 292(5526), 2434-2436 (2001)
74. Nduati R, John G, Mbori-Ngasha D et al.: Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 283(9), 1167-1174 (2000).
75. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM: Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African Vitamin A Study Group. Lancet 354(9177), 471-476 (1999).
76. The Breastfeeding and HIV International Transmission Study (BHITS) Group. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J. Infect. Dis. 189, 2154-2166 (2004).
77. Taha TE, Hoover DR, Kumwenda NI et al.: Late postnatal trarsmission of HIV-1 and associated factors. J. Infect. Dis. 196(1), 10-14 (2007).
78. Becquet R, Bland R, Leroy V et al.: Duration, pattern of breastfeeding and postnatal transmission of HIV:-pooled analysis of individual data from a West and South African cohort study. Presented at: The 7th Conference on Retroviruses and Opportunistic Infections. San Francisco Marriott, San Francisco, CA. USA, 30 January-2. February 2000.
79. Coovadia HM, Rollins NC, Bland RM et al.: Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 369(9567), 1107-1116 (2007).
80. Illiff P, Piwoz E, Tavengwa NV et al.: Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS 19, 699-708 (2005).
81. Kuhn L, Aldrovandi G M, Sin kala M et al.: Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N. Engl. J. Med. 359(2), 130-141 (2008).
82. Thior I, Lockman S, Smeaton LM et al.: Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA 296(7), 794-805 (2006).
83. Becquet R, Bequet L, Ekouevi DK et al.: Two-year morbidity-mortality and alternatives to prolonged breast-feeding among children born to HIV-infected mothers in Cote d'Ivoire. PLoS Med. 4(1), e17 (2007).
84. Rollins NC, Becquet R, Bland RM, Coutsoudis A, Coovadia HM, Newell ML: Infant feeding, HIV transmission and mortality at 18 months: the need for appropriate choices by mothers and prioritization within programmes. AIDS 22(17), 2349-2357 (2008).
85. Becquet R, Ekouevi DK, Viho I et al.: Acceptability of exclusive breast-feeding with early cessation to prevent HIV transmission through breast milk, ANRS 1201/1202 Ditrame Plus, Abidjan, Cote d'Ivoire. J Acquir. Immune Defic. Syndr. 40(5), 600-608 (2005).
86. Bland RM, Little KE, Coovadia HM, Coursoudis A, Rollins NC, Newell ML: Intervention to promote exclusive breastfeeding for the first 6 months of life in a high HIV prevalence area. AIDS 22(7), 883-891 (2008).
87. Bland RM, Rollins NC, Coovadia HM, CoutsoudisA, Newell ML: Infant feeding. counseling for HIV-infiected and uninfected women: appropriateness of choice and practice. Bull., World Health Organ. 85(4), 289-296 (2007).
88. De Vincenzi I: Kesho-Bora study group. HIV free survival at 12 months among children born to HIV-infected women receiving antiretrovirals from 34 to 36 weeks of pregnancy. Presented at: The 15th Conference on Retraviruses and Opportunistic Infections. Boston, MA, USA, 3-5 February 2008 (Abstract 638).
89. Thomas T, Masaba R, Ndivo R et at.: Prevention of mother-to-child transmission of HIV-1 among breastfeeding mothers using HAART: the Kisumu breastfeeding study, Kisumu, Kenya, 2003-2007. Presented at: The 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-5 February 2008 (Abstract 45LB).
90. van der Horst C, Chasela C, Ahmed Y et al.: Modifications ofa large HIV prevention clinica trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi. Contemp. Clin Trials 30(1), 24-33 (2009).
91. Bedri A, Gudetta B, Isehak A et al.: Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda an analysis of three randomised controlled trials. Lancet 372(9635), 300-313 (2008).
92. Kilewc, C, Karlsson K, Massawe A et al.: Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir. Immune Defic. Syndr. 48(3), 315-323 (2008).
93. Kumwenda NI, Hoover DR, Mofenson LM et al.: Extended antiretroviral prophylaxis to reduce breast-milk, HIV-1 transmission. N. Engl. J. Med. 359(2), 119-129 (2008).
94. Ronsmans C, Graham WJ. Maternal mortality: who when, where, and why. Lancet 368(9542), 1189-1200 (2006).
95. Collin SM, Chisenga MM, Kasonka L et al.: Factors associated with postpartum physical and mental morbidity among women with known HIV status in Lusaka, Zambia. AIDS Care 18(7), 812-820 (2006).
96. Walson JL, Brown ER, Otieno PA et al.: Morbidity amohg HIV-1-infected mothers in Kenya: prevalence and correlates of illness during 2-year postpartum follow-up. J Acquir. Immune Defic. Syndr. 46(2), 208-215 (2007).
97. Zvandasara P, Hargrove JW, Ntozini R et al.: Mortality and morbidity among-postpartum HIV-positive and HIV-negative women in Zimbabwe: risk factors, causes, and, impact of single-dose postpartum vitamin A supplementation. J. Acquir. Immune Defic. Syndr. 43(1), 107-116 (2006).
98. Chatterjee A,-Bosch RJ, Hunter DJ, Fataki MR, Msamanga GI, Fawzi WW: Maternal disease stage and child undernutrition in relation to mortality among children born to HIV-infected women in Tanzania. J. Acquir. Immune Defic. Syndr. 46(5), 599-606 (2007).
99. Nakiyingi JS, Bracher M, Whitworth JA et al.: Child survival in relation to mother's HIV infection and survival: evidence from a Ugandan cohort study. AIDS 17(12), 1827-1834 (2003).
100. Rollins N, Little K, Mzolo S, Horwood C, Newell ML: Surveillance of mother-to-child transmission prevention programmes at immunization clinics: the case for universal screening. AIDS 21(10), 1341-1347 (2007).
101. Little K, Newell ML, Luo C, Ngongo N, Borja MC, McDermott P: Estimating the number of vertically HIV-infected children eligible for antiretroviral treatment in resource-limited settings. Int. J. Epidemiol. 36(3), 679-687 (2007).
102. Prendergast A, Mphatswe W, Tudor-Williams G et al.: Early virological suppression with thlree-class antiretroviral therapy in HIV-infected African infants. AIDS 22(11), 1333-1343 (2008).
103. Violari A, Cotton MF, Gibb DM et al.: Early antirctroviral therapy and mortality among HIV-infected infants, N. Engl. J. Med. 359(21), 2233-2244 (2008).
104. Fischer A, Lejczak C, Lambert C et al.: Simple DNA extraction method for dried blood spots and comparison of two PCR assays for diagnosis of vertical human immunodeficiency virus type 1 transmission in Rwanda. J. Clin. Microbiol. 42(1), 16-20 (2004).
105. Rouet F, Ekouevi DK, Chaix ML et al.: Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43(6), 2709-2717 (2005).
106. Rouet F, Sakarovitch C, Msellati P et al.: Pediatric viral human immunodeficiency virus type 1 RNA levels, timing of infection, and disease progression in African HIV-1-infected children. Pediatrics 112(4), e289 (2003).
107. Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS: Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J. Acquir. Immune Defic. Syndr. 38(5), 615-617 (2005).
108. Sherman GG, Cooper PA, Covadia AH et al.: Polymerase chain reaction for diagnosis of human immunodeficiency virus infection in infancy in low resource settings. Pediatr. Infect. Dis. 124(11), 993-997 (2005).
109. Brown E, Chi BH, Read JS et al.: Determining an optimal testing strategy for infants at risk for mother-to-child transmission of HIV-1 during the late postnatal period. AIDS 22(17), 2341-2346 (2008).
110. Bertozzi SM, Laga M, Bautista-Arredondo S, Coutinho A: Making HIV prevention programmes work. Lancet 372 (9641), 831-844 (2008).
111. Merson MH, O'Malley J, Serwadda D, Apisuk C: The history and challenge of HIV prevention. Lancet 372(9637), 475-488 (2008).
112. Morris K: The effect of HIV/AIDS on international health. Lancet Infect. Dis. 8(8), 468-469 (2008).
113. Piot P. Bartos M, Larson H, Zewdie D. Marie P: Coming to terms with complexity: a call to action for HIV prevention. Lancet 372(9641), 845-859 (2008).
114. Horton R, Das P: Putting prevention at the forefront of HIV/AIDS. Lancet 372, 421-422 (2008).
115. Coovadia H, Bland R: From Alma-Ata to Agincourt: primary healthcare in AIDS. Lancet 372(9642), 866-868 (2008).